FibromyalgiaWRAP
A Systematic Approach to
Optimizing Patient Care—
Focus on Multimodal Therapy and Dual
Reuptake Receptor (SNRI) Inhibition

HealthWRAP CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Intended Audience:

This program is designed for all practitioners with the following specialties or subspecialties: Rheumatologists, primary care physicians, psychiatrists, neurologists, women health care specialists, OB-GYN specialists, nurse practitioners, and other health care providers who treat fibromyalgia.

Registration:

Enrollment for this HealthWRAP is complimentary, and clinicians are invited to participate in this CME-certified HealthWRAPs and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

Supported by an independent educational grant from Forest Pharmaceuticals, Inc.

Accreditation Statement for Jointly-Sponsored Programs:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty and Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty:

Robert Bennett, MD
Professor of Medicine and Nursing Research
Oregon Health and Science University (OHSU)
Portland, Oregon

Faculty Disclosures:

Dr. Robert Bennett discloses that he has been a consultant to Pfizer, Jazz Pharmaceuticals, and Schwarz Pharma, and he has received research funding from Merck, Schwarz Pharma, and Jazz Pharmaceuticals.

Educational Objectives:

Physicians, pharmacists, and other healthcare providers will:

• Learn to recognize the clinical, behavioral, physiological, and psychiatric signs and symptoms of individuals suffering from FM.
• Learn how to evaluate the safety and effectiveness of pharmacologic agents indicated and/or currently being evaluated for FM, with a focus on norepinephrine reuptake inhibitors (NRIs).
• Learn how to evaluate the drug interaction profiles of pharmacologic agents indicated for FM.
• Learn how to evaluate multiple decision points to guide screening, diagnosing, and evaluation patients for FM.
• Learn how to use evidence-supported, pharmacologic approaches for optimizing management of FM, with an emphasis on NRIs and their impact on patient symptom relief and other disease metrics.
• Learn how to use evidence-supported, pharmacologic approaches for optimizing management of FM, with a focus on duration of therapy, dose adjustment, and long-term maintenance and/or discontinuation of therapy.
• Learn how to implement and participate in multimodal approaches—counseling, pharmacological, support groups, behavioral approaches, and other resources—in order to provide comprehensive management of patients with FM.

Disclaimer:

Copyright © 2008 by Pharmatecture, LLC. All rights reserved. Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this HealthWRAP reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this HealthWRAP is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this HealthWRAP is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This HealthWRAP is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This HealthWRAP is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2008 All rights reserved